DrugPatentWatch Database Preview

Novartis Pharms Corp Company Profile

NOVARTIS PHARMS CORP has fifty-nine approved drugs.

There are one hundred and twelve US patents protecting NOVARTIS PHARMS CORP drugs.

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-001	Mar 30, 2015		RX	Yes	No	9,283,209	➤ Sign Up	Y	Y		➤ Sign Up
Novartis Pharms Corp	ZYKADIA	ceritinib	CAPSULE;ORAL	205755-001	Apr 29, 2014		RX	Yes	Yes	9,416,112	➤ Sign Up	Y	Y		➤ Sign Up
Novartis Pharms Corp	SIGNIFOR LAR KIT	pasireotide pamoate	FOR SUSPENSION;INTRAMUSCULAR	203255-005	Jun 29, 2018		RX	Yes	No		➤ Sign Up				➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis Pharms Corp	ZOFRAN	ondansetron hydrochloride	TABLET;ORAL	020103-003	Aug 27, 1999	4,753,789*PED	➤ Sign Up
Novartis Pharms Corp	ZOFRAN	ondansetron hydrochloride	TABLET;ORAL	020103-002	Dec 31, 1992	5,578,628*PED	➤ Sign Up
Novartis Pharms Corp	PATANOL	olopatadine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	020688-001	Dec 18, 1996	4,871,865	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Ophthalmic Solution	10.5%	➤ Subscribe	2012-02-29
➤ Subscribe	Ophthalmic Solution	0.10%	➤ Subscribe	2006-07-17
➤ Subscribe	Ophthalmic Solution	0.00%	➤ Subscribe	2009-02-19
➤ Subscribe	Nasal Spray	0.665 mg/ Spray	➤ Subscribe	2009-06-29
➤ Subscribe	Otic Suspension	0.3%/0.1%	➤ Subscribe	2012-07-31
➤ Subscribe	Tablets	180 mg	➤ Subscribe	2015-10-23
➤ Subscribe	Ophthalmic Emulsion	0.05%	➤ Subscribe	2014-05-01
➤ Subscribe	Tablets	50 mg and 75 mg	➤ Subscribe	2014-01-07
➤ Subscribe	Injection	1 mg/mL, 50 mL vials	➤ Subscribe	2011-12-16
➤ Subscribe	Tablets	250 mg	➤ Subscribe	2011-03-14
➤ Subscribe	Ophthalmic Solution	0.003%	➤ Subscribe	2015-12-30
➤ Subscribe	Ophthalmic Solution	0.20%	➤ Subscribe	2008-09-08
➤ Subscribe	Ophthalmic Solution	0.7%	➤ Subscribe	2015-09-10
➤ Subscribe	Ophthalmic	0.50%	➤ Subscribe	2005-12-22
➤ Subscribe	Ophthalmic Suspension	0.3%	➤ Subscribe	2015-12-21
➤ Subscribe	Tablets	90 mg and 360 mg	➤ Subscribe	2015-10-19
➤ Subscribe	Tablets	180 mg	➤ Subscribe	2016-04-28
➤ Subscribe	Injection	100 mg/mL, 2.5 mL vials	➤ Subscribe	2007-09-24
➤ Subscribe	Tablets	12.5 mg and 25 mg	➤ Subscribe	2014-02-04
➤ Subscribe	Oral Solution	4 mg/5 mL	➤ Subscribe	2004-12-20

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2015 00047	Denmark	➤ Sign Up	PRODUCT NAME: CERITINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/15/999 (C(2015)3218) 20150506
2015 00050	Denmark	➤ Sign Up	PRODUCT NAME: CERITINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/15/999 20150508
C0045	France	➤ Sign Up	PRODUCT NAME: TRAVOPROST; REGISTRATION NO/DATE: EU/1/01/199/001 20011127
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.